Health Canada Approves InterMune's Esbriet to Treat Fatal Lung Disease RTT News IPF is a progressive and uniformly fatal disease that affects approximately 5,000 to 8,000 Canadians, is characterized by scarring of lung tissue, and has a similar short life expectancy to that of many forms of cancer, including lung, colorectal and ... Canadian health regulators approve InterMune's fibrosis drug |
